Scipher Medicine Welcomes Sam Davis As General Counsel



WALTHAM, Mass., Sept. 24, 2021 (GLOBE NEWSWIRE) – Scipher Medicine, a precision immunology company linking patients to their most effective therapies, today announced the appointment of Sam A. Davis, JD, to the position legal advisor. Sam will lead all legal matters for the company, including strategic partnerships, future collaborations and financing transactions.

“We are very happy to welcome Sam to the Scipher team,” said Alif Saleh, CEO of Scipher Medicine. “Sam’s life sciences background and his innovative vision of how the law can facilitate and accelerate deal making puts him in a unique position to guide us through our next phase of meaningful growth. ”

“Scipher is developing new, exciting and innovative solutions to address some of the biggest challenges in healthcare today, using cutting edge technology,” Sam said. “It is a privilege to be part of a team that enables healthcare professionals to reduce excessive waste and improve patient outcomes. “

Sam brings a wealth of experience as a leading life sciences lawyer to various executive positions at EQRx, Goodwin Proctor LLP and McDermott and Will & Emery LLP. Prior to joining Scipher, Sam was Associate General Counsel, Vice President of Legal Affairs at EQRx, where he led all legal matters, including private and public finance, multiple licenses and global collaborations, and payor partnerships.

About PrismRA®
PrismRA, a liquid signature test, is a revolutionary breakthrough in bringing precision medicine to the treatment of rheumatoid arthritis, which affects 20 million patients worldwide. From a routine blood test, the PrismRA test analyzes an individual’s molecular signature, helping to identify who is unlikely to respond adequately to TNFi therapy, the world’s best-selling class of drugs, so that non-responders can be prescribed an effective alternative therapy and avoid unnecessary dose escalations or drug cycles. Providers now have objective data to guide treatment decision making and give patients the best chance to meet treatment goals and improve clinical outcomes. For more information, please visit

About Scipher Medicine®
Scipher Medicine, a precision immunology company, believes patients deserve straightforward answers to treatment options based on scientifically supported data. Take advantage of our exclusive Spectra® platform and artificial intelligence, we market liquid tests that reveal the unique molecular signature of a disease and combine that signature with the most effective therapy, ensuring optimal treatment from day one. The unprecedented amount of molecular patient data generated by our tests further stimulates the discovery and development of new and more effective therapies. We partner with payers, suppliers and pharmaceutical companies across the healthcare value chain to bring precision medicine to autoimmune diseases. Visit and follow Scipher on Twitter, Facebook and LinkedIn.



About Author

Comments are closed.